Neuland Laboratories' Q3 FY 2025-26 Quarterly Results

Result Summary

• Neuland Laboratories Ltd reported a 13.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.4%.
• Its expenses for the quarter were up by 1.7% QoQ and 19.2% YoY.
• The net profit decreased 58.1% QoQ and decreased 60.1% YoY.
• The earnings per share (EPS) of Neuland Laboratories Ltd stood at 31.62 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Neuland Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily focusing on developing and manufacturing active pharmaceutical ingredients (APIs). The company is known for its extensive portfolio of APIs, providing strong support to the pharmaceutical sector. Neuland Laboratories operates within the highly competitive pharmaceutical industry, which demands constant innovation and adherence to stringent regulatory standards. Recent major developments specific to Neuland Laboratories Ltd in terms of strategic initiatives or partnerships are not available in the provided data.

Revenue

For the third quarter of the fiscal year 2026 (Q3FY26), Neuland Laboratories Ltd reported a total income of ₹447.76 crores. This marked a significant decrease of 13.2% from the preceding quarter (Q2FY26), where total income was ₹516.07 crores. However, when compared to the third quarter of the previous fiscal year (Q3FY25), there was an increase of 11.4%, with total income at ₹401.94 crores during that period. This indicates variability in quarterly performance contrasted with a year-over-year growth.

Profitability

The company registered a profit before tax of ₹54.48 crores in Q3FY26, showing a drastic decline of 57.9% from ₹129.44 crores in the previous quarter (Q2FY26). Additionally, there was a 57.4% decrease compared to the profit before tax of ₹127.76 crores in Q3FY25. The tax expense for Q3FY26 was ₹13.90 crores, representing a reduction of 57.3% from Q2FY26 and a 46.9% decrease from Q3FY25. Consequently, the profit after tax stood at ₹40.57 crores, which was a 58.1% decrease from ₹96.85 crores in Q2FY26 and a 60.1% decline from ₹101.59 crores in Q3FY25. Earnings per share also mirrored these trends, declining to ₹31.62 in Q3FY26 from ₹75.49 in Q2FY26 and ₹79.18 in Q3FY25.

Operating Metrics

The total expenses for Neuland Laboratories in Q3FY26 were ₹393.29 crores, which reflected a slight increase of 1.7% over the previous quarter's expenses of ₹386.64 crores. However, there was a notable 19.2% rise from the total expenses of ₹329.95 crores in Q3FY25. The data illustrates a consistent upward trend in expenses over the year. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not provided in the available data, limiting further detailed analysis in this area. The overall financial metrics demonstrate fluctuations in revenue and profitability, while expenses have shown an upward trend year-on-year.